GeoVax to Present at the 2024 BIO CEO & Investor Conference
19 Février 2024 - 3:00PM
via NewMediaWire
– GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, announced today that its
Chairman and CEO, David Dodd, will present at the 2024 BIO CEO
& Investor Conference, taking place in-person in New York, NY
on February 26-27, 2024.
Presentation Details:Presenter:
David Dodd, Chairman &
CEODate/Time: February 26,
2024, 4:15 pm
ETLocation:
New York Marriott MarquisRegistration: BIO
CEO & Investor Conference
GeoVax senior management will also conduct
one-on-one meetings during the conference. For more information or
to schedule a meeting, please visit the conference page here or
contact GeoVax Investor Relations.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in three
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary
vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the
current authorized COVID-19 vaccines are insufficient, and as a
booster vaccine in patients with chronic lymphocytic leukemia
(CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial
evaluating the vaccine as a more robust, durable COVID-19 booster
among healthy patients who previously received the mRNA vaccines.
GeoVax has a leadership team who have driven significant value
creation across multiple life science companies over the past
several decades. For more information, visit our website:
www.geovax.com.
Company
Contact: |
|
Investor
Relations Contact: |
|
Media
Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
GeoVax Labs (NASDAQ:GOVX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
GeoVax Labs (NASDAQ:GOVX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024